Episode economics
The per-case math of personalized surgery, now that the episode is mandatory.
For a decade, patient-specific planning and implants were sold as clinical elegance — and bought rarely, because under fee-for-service the buyer of “fewer revisions” was nobody. The mandate rewires that. When the facility is accountable for the whole episode, the beneficiary of a better-fitting joint is the facility itself.
The three numbers that matter
- What dissatisfaction costs. With recent systematic reviews putting residual knee-replacement dissatisfaction at roughly 7–10% (definition-dependent) and alignment implicated, a prolonged recovery or complication inside the episode window is spend the accountable provider now carries. Most revisions fall years later, outside the window.
- What personalization costs. Per-case, no capital: planning fees measured in hundreds, not the capital walls of robotics programs. The comparison isn’t “personalized vs. standard implant cost” — it’s “per-case planning fee vs. probability-weighted revision cost you now own.”
- What changes under ACCESS. Under ACCESS (live July 2026, code G0677) patients who won’t have surgery can be cared for as reimbursed co-management rather than written off.
Fee-for-service asked: “what does this device cost?” The episode asks: “what does this episode cost, and who keeps the difference when it goes well?” Personalization only ever made economic sense in the second question — and the second question is now the law.
Run your own numbers
Take your last 100 episodes: revision + readmission count inside the window, times your average episode overrun, versus 100 × a per-case planning fee. Run it on your own cases before believing anyone’s estimate, including ours.
Start the conversation →Not clinical, legal, or financial advice. MSKvalue assembles independent best-of-class products with the American Joint Replacement Registry as the outcomes backbone.